1. Update From Seattle 2017

2. Update From Seattle 2017 (cont)

3. HIV Treatment

4. Dual ART – DTG + RPV SWORD-1 and SWORD-2

5. Dual ART – DTG + RPV SWORD-1 and SWORD-2 (cont)

6. Dual ART – CAB + RPV LATTE Wk 144 Results

7. Dual ART – CAB + RPV LATTE Wk 144 Results (cont)

8. Dual ART – CAB + RPV LATTE Wk 144 Results (cont)

9. Initial ART With TAF vs TDF Wk 144 Follow-Up

10. Dual ART LAMIDOL Study (ANRS 167)

11. Investigational Agent – Bictegravir Phase 2 Study Results

12. Investigational Agent – Doravirine DRIVE Study – Wk 48 Results

13. Investigational Agent – Doravirine DRIVE Study – Wk 48 Results (cont)

14. Investigational Agent – Doravirine DRIVE Study – Wk 48 Results (cont)

15. Investigational Agent – Capsid Inhibitor GS-CA1

16. Additional Investigational Agents Phase 1 or Phase 2

17. Comorbidities and Aging

18. Unrestricted Access of DAA Agents Rapid Uptake in Patients With HIV/HCV Coinfection

19. DAA Agents Treatment as Prevention in MSM?

20. Risk of HCC in Patients With HIV/HCV Coinfection After SVR (HCV) GEHEP-002 Cohort

21. Risk of HCC in Patients With HIV/HCV Coinfection After SVR GEHEP-002 Cohort (cont)

22. Risk of HCC in Patients With HIV/HCV Coinfection After SVR GEHEP-002 Cohort (cont)

23. Hepatic Steatosis The STERAL Study

24. Hepatic Steatosis The STERAL Study (cont) – Wk 48 Results

25. BMI and Risk for SNAEs

26. BMI and Risk for SNAEs (cont)

27. Aging and Frailty The ALIVE Cohort

28. Aging and Frailty The ALIVE Cohort (cont)

29. Summary and Clinical Implications

30. Abbreviations

31. Abbreviations (cont)

32. Abbreviations (cont)